BeiGene nabs another PD-1 approval in China. Can partner Novartis carry the success to US and Europe? Biotech's top 10 money raisers of 2021 Jury acquits DaVita, ex-CEO on all counts in landmark antitrust trial, dealing major blow to DOJ Another SPAC deal cracks as spine implant maker Accelus calls off Nasdaq plans Oft-chided Lupin dinged by FDA at Indian pharmaceutical ingredients plant Fore tees up new CEO, 5 months after ousting former chief executive on insider trading charges AstraZeneca strengthens ties with Chinese cancer diagnostic developer AmoyDx Amid losses, Bright Health to exit 6 markets Bayer CEO gets proxy brawlers' backing, but exec compensation still in investors' crosshairs: report UPDATE: TG disbands cancer program after pulling FDA request for U2 combo therapy Natus Medical to go private in $1.2B private equity acquisition deal Blue Spark fires up $40M funding for remote monitoring wearables Kaiser Permanente doubles affordable housing investment to $400M Featured Story | By Kevin Dunleavy BeiGene has won approval in China for tislelizumab as a treatment for second-line patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). It is the eighth approval in the last three years in its home country for the drug, which has yet to gain a nod outside of China. Partner Novartis hopes to change that with filings for the drug in the U.S. and Europe. read more |
| |
|---|
|
Top Stories By Max Bayer 2021 marked the second consecutive year of record-breaking private financing for biotechs, with more than $28 billion raised. The total haul is a 26% increase from 2020, and the stunning dollar amounts came even as the public market depreciated throughout the year. Here's our look at the 10 biotechs that raked in the largest VC investments. read more By Heather Landi A jury in Denver acquitted dialysis provider DaVita and its former CEO Kent Thiry on Friday of charges that they conspired with competitors not to hire each other's key employees. The verdict marks a massive defeat for government prosecutors who had targeted the dialysis giant’s non-poaching agreements with rival companies in an unprecedented criminal conspiracy case. read more By Conor Hale After inking a $482 million deal to go public late last year, Accelus and its SPAC partner, CHP Merger Corp., have called it quits. read more By Fraiser Kansteiner Lupin’s active pharmaceutical ingredient (API) plant in Tarapur, India, has been slapped with a Form 483, the company confirmed in a filing on the Bombay Stock Exchange. The FDA issued its observations after inspecting Lupin’s facility between March 22 and April 4, the company said. read more By Gabrielle Masson Fore Biotherapeutics has installed Matthew Ros as new CEO and director of the board nearly five months after ousting former CEO Usama Malik, who is facing insider trader charges related to a separate company. read more By Conor Hale AstraZeneca is once again tapping the Shanghai-based developer Amoy Diagnostics for new companion tests to be paired up with its cancer medicines in China, Japan and the EU. read more By Paige Minemyer Bright Health will exit six markets in a bid to focus its business following a year of losses. read more By Fraiser Kansteiner Prominent proxy brawlers Institutional Shareholder Services (ISS) and Glass Lewis have endorsed Bayer’s leadership but stopped short of blessing its “excessive” executive compensation plans, Bloomberg News first reported. read more By Max Bayer TG Therapeutics is winding down its oncology program after removing the FDA-approved cancer med Ukoniq from the market in two indications that were granted accelerated approval in addition to withdrawing an approval request for a combo med dubbed U2. read more By Andrea Park Two decades after hitting the Nasdaq as a publicly traded company in 2001, Natus Medical is saying goodbye to all that. read more By Andrea Park Amid the rollout of the latest version of its TempTraq remote body temperature monitor, Blue Spark has secured $40 million to speed up and expand that rollout and advance the development of other remote patient monitoring technologies. read more By Robert King Kaiser Permanente has doubled its investment in affordable housing to $400 million as major payers and health systems turn to housing to address health equity gaps. read more |
